Welcome to LookChem.com Sign In|Join Free

CAS

  • or

664364-28-7

Post Buying Request

664364-28-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

664364-28-7 Usage

General Description

Tert-butyl (3Z)-3-(2-ethoxy-2-oxoethylidene)pyrrolidine-1-carboxylate is a chemical compound with the molecular formula C13H21NO4. It is a pyrrolidine derivative that is often used in organic synthesis and pharmaceutical research. The tert-butyl group provides steric hindrance, making the compound more stable and less reactive. The presence of the ethoxy and oxoethylidene groups confers certain chemical reactivity and potential bioactivity to the compound, making it a versatile building block in the synthesis of various organic compounds. Its structural characteristics make it a potentially valuable scaffold for designing new drugs and functional materials. Overall, tert-butyl (3Z)-3-(2-ethoxy-2-oxoethylidene)pyrrolidine-1-carboxylate is a compound with diverse applications in chemical and pharmaceutical research.

Check Digit Verification of cas no

The CAS Registry Mumber 664364-28-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,4,3,6 and 4 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 664364-28:
(8*6)+(7*6)+(6*4)+(5*3)+(4*6)+(3*4)+(2*2)+(1*8)=177
177 % 10 = 7
So 664364-28-7 is a valid CAS Registry Number.

664364-28-7Relevant articles and documents

Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery

King, Thomas A.,Stewart, Hannah L.,Mortensen, Kim T.,North, Andrew J. P.,Sore, Hannah F.,Spring, David R.

, p. 5219 - 5229 (2019/08/12)

In recent years the pharmaceutical industry has benefited from the advances made in fragment-based drug discovery (FBDD) with more than 30 fragment-derived drugs currently marketed or progressing through clinical trials. The success of fragment-based drug

BIARYL DERIVATIVE AS GPR120 AGONIST

-

Paragraph 0267, (2017/11/17)

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 664364-28-7